Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012).
Monge S, Díez M, Alvarez M, Guillot V, Iribarren JA, Palacios R, Delgado R, Jaén A, Blanco JR, Domingo P, Portilla J, Pérez Elías MJ, Garcia F; Cohorte de la Red de Investigación en Sida (CoRIS). Monge S, et al. Among authors: portilla j. Clin Microbiol Infect. 2015 Jan;21(1):105.e1-5. doi: 10.1016/j.cmi.2014.08.007. Epub 2014 Oct 29. Clin Microbiol Infect. 2015. PMID: 25636937 Free article.
Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates.
García-Guerrero J, Sáiz de la Hoya P, Portilla J, Marco A, Sánchez-Payá J, Moreno S; Estudio de Resistencias en Prisiones Group. García-Guerrero J, et al. Among authors: portilla j. Eur J Clin Microbiol Infect Dis. 2006 Nov;25(11):695-701. doi: 10.1007/s10096-006-0206-z. Eur J Clin Microbiol Infect Dis. 2006. PMID: 17043836
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team. Molina JM, et al. Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18. Lancet Infect Dis. 2012. PMID: 22015077 Clinical Trial.
Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
Macías J, Viloria MM, Rivero A, de los Santos I, Márquez M, Portilla J, Di Lello F, Camacho A, Sanz-Sanz J, Ojeda G, Mata R, Gómez-Mateos J, Pineda JA; FIBROCEL study group. Macías J, et al. Among authors: portilla j. Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):2083-8. doi: 10.1007/s10096-012-1546-5. Epub 2012 Jan 19. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22258426
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI, Pulido F, Martinez E, Arrizabalaga J, Domingo P, Portilla J, Ocampo A, Muñoz J, Torres R, Arribas JR; GESIDA-6008-KRETA Study Group. Bernardino JI, et al. Among authors: portilla j. J Antimicrob Chemother. 2013 Jun;68(6):1373-81. doi: 10.1093/jac/dks540. Epub 2013 Feb 5. J Antimicrob Chemother. 2013. PMID: 23386261 Clinical Trial.
Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort.
Torres M, González C, del Romero J, Viciana P, Ocampo A, Rodríguez-Fortúnez P, Masiá M, Blanco JR, Portilla J, Rodríguez C, Hernández-Novoa B, del Amo J, Ortiz M; CoRIS-HPV Study Group. Torres M, et al. Among authors: portilla j. J Clin Microbiol. 2013 Nov;51(11):3512-20. doi: 10.1128/JCM.01405-13. Epub 2013 Aug 21. J Clin Microbiol. 2013. PMID: 23966501 Free PMC article.
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Perez I, Gatell JM; ATADAR Study Group. Martinez E, et al. Among authors: portilla j. HIV Med. 2014 Jul;15(6):330-8. doi: 10.1111/hiv.12121. Epub 2014 Jan 12. HIV Med. 2014. PMID: 24417772 Free article. Clinical Trial.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
348 results